Kirsten Bouchelouche1, Peter L Choyke2. 1. Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark. 2. Chief, Molecular Imaging Program, Center for Cancer Research, National Cancer Institute (NCI), Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: In recent years, a large number of reports have been published on prostate-specific membrane antigen (PSMA)/PET in prostate cancer (PCa). This review highlights advances in PSMA PET in PCa during the past year. RECENT FINDINGS: PSMA PET/computed tomography (CT) is useful in detection of biochemical recurrence, especially at low prostate-specific antigen (PSA) values. The detection rate of PSMA PET is influenced by PSA level. For primary PCa, PSMA PET/CT shows promise for tumour localization in the prostate, especially in combination with multiparametric MRI (mpMRI). For primary staging, PSMA PET/CT can be used in intermediate and high-risk PCa. Intraoperative PSMA radioligand guidance seems promising for detection of malignant lymph nodes. While the use of PSMA PET/MRI in primary localized disease is limited to high and intermediate-risk patients and localized staging, in the recurrence setting, PET/MRI can be particularly helpful when the lesions are subtle. PSMA PET/CT is superior to choline PET/CT and other conventional imaging modalities. SUMMARY: Molecular imaging with PSMA PET continues to pave the way for personalized medicine in PCa.However, large prospective clinical studies are still needed to fully evaluate the role of PSMA PET/CT and PET/MRI in the clinical workflow of PCa.
PURPOSE OF REVIEW: In recent years, a large number of reports have been published on prostate-specific membrane antigen (PSMA)/PET in prostate cancer (PCa). This review highlights advances in PSMA PET in PCa during the past year. RECENT FINDINGS:PSMA PET/computed tomography (CT) is useful in detection of biochemical recurrence, especially at low prostate-specific antigen (PSA) values. The detection rate of PSMA PET is influenced by PSA level. For primary PCa, PSMA PET/CT shows promise for tumour localization in the prostate, especially in combination with multiparametric MRI (mpMRI). For primary staging, PSMA PET/CT can be used in intermediate and high-risk PCa. Intraoperative PSMA radioligand guidance seems promising for detection of malignant lymph nodes. While the use of PSMA PET/MRI in primary localized disease is limited to high and intermediate-risk patients and localized staging, in the recurrence setting, PET/MRI can be particularly helpful when the lesions are subtle. PSMA PET/CT is superior to choline PET/CT and other conventional imaging modalities. SUMMARY: Molecular imaging with PSMA PET continues to pave the way for personalized medicine in PCa.However, large prospective clinical studies are still needed to fully evaluate the role of PSMA PET/CT and PET/MRI in the clinical workflow of PCa.
Authors: Sebastian Mannweiler; Peter Amersdorfer; Slave Trajanoski; Jonathan A Terrett; David King; Gabor Mehes Journal: Pathol Oncol Res Date: 2008-09-18 Impact factor: 3.201
Authors: Christian Uprimny; Alexander Stephan Kroiss; Clemens Decristoforo; Josef Fritz; Elisabeth von Guggenberg; Dorota Kendler; Lorenza Scarpa; Gianpaolo di Santo; Llanos Geraldo Roig; Johanna Maffey-Steffan; Wolfgang Horninger; Irene Johanna Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2017-01-31 Impact factor: 9.236
Authors: Lars Budäus; Sami-Ramzi Leyh-Bannurah; Georg Salomon; Uwe Michl; Hans Heinzer; Hartwig Huland; Markus Graefen; Thomas Steuber; Clemens Rosenbaum Journal: Eur Urol Date: 2015-06-25 Impact factor: 20.096
Authors: Sarah M Schwarzenboeck; Isabel Rauscher; Christina Bluemel; Wolfgang P Fendler; Steven P Rowe; Martin G Pomper; Ali Afshar-Oromieh; Ken Herrmann; Matthias Eiber Journal: J Nucl Med Date: 2017-07-07 Impact factor: 10.057
Authors: Steven P Rowe; Alexander Drzezga; Bernd Neumaier; Markus Dietlein; Michael A Gorin; Michael R Zalutsky; Martin G Pomper Journal: J Nucl Med Date: 2016-10 Impact factor: 10.057
Authors: Hojjat Ahmadzadehfar; Kambiz Azgomi; Stefan Hauser; Xiao Wei; Anna Yordanova; Florian C Gaertner; Stefan Kürpig; Holger Strunk; Markus Essler Journal: J Nucl Med Date: 2016-09-22 Impact factor: 10.057
Authors: Jeffrey S Ross; Christine E Sheehan; Hugh A G Fisher; Ronald P Kaufman; Prabhjot Kaur; Karen Gray; Iain Webb; Gary S Gray; Rebecca Mosher; Bhaskar V S Kallakury Journal: Clin Cancer Res Date: 2003-12-15 Impact factor: 12.531
Authors: Ali Afshar-Oromieh; Tim Holland-Letz; Frederik L Giesel; Clemens Kratochwil; Walter Mier; Sabine Haufe; Nils Debus; Matthias Eder; Michael Eisenhut; Martin Schäfer; Oliver Neels; Markus Hohenfellner; Klaus Kopka; Hans-Ulrich Kauczor; Jürgen Debus; Uwe Haberkorn Journal: Eur J Nucl Med Mol Imaging Date: 2017-05-12 Impact factor: 9.236
Authors: Florian Sterzing; Clemens Kratochwil; Hannah Fiedler; Sonja Katayama; Gregor Habl; Klaus Kopka; Ali Afshar-Oromieh; Jürgen Debus; Uwe Haberkorn; Frederik L Giesel Journal: Eur J Nucl Med Mol Imaging Date: 2015-09-25 Impact factor: 9.236
Authors: Hao G Nguyen; Crystal S Conn; Yae Kye; Lingru Xue; Craig M Forester; Janet E Cowan; Andrew C Hsieh; John T Cunningham; Charles Truillet; Feven Tameire; Michael J Evans; Christopher P Evans; Joy C Yang; Byron Hann; Constantinos Koumenis; Peter Walter; Peter R Carroll; Davide Ruggero Journal: Sci Transl Med Date: 2018-05-02 Impact factor: 17.956
Authors: Yi Zhao; Naomi Morka; Benjamin Scott S Simpson; Alex Freeman; Alex Kirkham; Daniel Kelly; Hayley C Whitaker; Mark Emberton; Joseph M Norris Journal: BMJ Open Date: 2021-12-10 Impact factor: 2.692
Authors: Yi Zhao; Benjamin S Simpson; Naomi Morka; Alex Freeman; Alex Kirkham; Daniel Kelly; Hayley C Whitaker; Mark Emberton; Joseph M Norris Journal: Cancers (Basel) Date: 2022-07-19 Impact factor: 6.575